Literature DB >> 2183719

Single-dose oral cefixime versus amoxicillin plus probenecid for the treatment of uncomplicated gonorrhea in men.

D W Megran1, K Lefebvre, V Willetts, W R Bowie.   

Abstract

In this randomized study, a single 800-mg oral dose of cefixime cured 96 of 97 men with uncomplicated gonococcal urethritis, compared with 44 cures of 46 men who received standard therapy with amoxicillin (3 g) plus probenecid (1 g). Both regimens were ineffective against coexistent infection with Chlamydia trachomatis and Ureaplasma urealyticum. Cefixime was well tolerated, and all side effects were mild and self-limited.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2183719      PMCID： PMC171586          DOI： 10.1128/AAC.34.2.355

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  7 in total

1.  The pharmacokinetic and bactericidal characteristics of oral cefixime.

Authors:  D C Brittain; B E Scully; T Hirose; H C Neu
Journal:  Clin Pharmacol Ther       Date:  1985-11       Impact factor: 6.875

2.  Eradication of Chlamydia trachomatis from the urethras of men with nongonococcal urethritis by treatment with amoxicillin.

Authors:  W R Bowie; E R Alexander; K K Holmes
Journal:  Sex Transm Dis       Date:  1981 Apr-Jun       Impact factor: 2.830

3.  Effect of treatment regimens for Neisseria gonorrhoeae on simultaneous infection with Chlamydia trachomatis.

Authors:  W E Stamm; M E Guinan; C Johnson; T Starcher; K K Holmes; W M McCormack
Journal:  N Engl J Med       Date:  1984-03-01       Impact factor: 91.245

4.  In vitro and in vivo antibacterial properties of FK 027, a new orally active cephem antibiotic.

Authors:  T Kamimura; H Kojo; Y Matsumoto; Y Mine; S Goto; S Kuwahara
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

5.  Tetracycline in nongonococcal urethritis. Comparison of 2 g and 1 g daily for seven days.

Authors:  W R Bowie; J S Yu; A Fawcett; H D Jones
Journal:  Br J Vener Dis       Date:  1980-10

6.  Comparative in vitro activity and beta-lactamase stability of FR 17027, a new orally active cephalosporin.

Authors:  H C Neu; N X Chin; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

7.  Bromothymol blue broth: improved medium for detection of Ureaplasma urealyticum (T-strain mycoplasma).

Authors:  J A Robertson
Journal:  J Clin Microbiol       Date:  1978-02       Impact factor: 5.948
  7 in total
  8 in total

1.  Management of gonococcal infection among adults and youth: New key recommendations.

Authors:  Lisa Pogany; Barbara Romanowski; Joan Robinson; Margaret Gale-Rowe; Cathy Latham-Carmanico; Christine Weir; Tom Wong
Journal:  Can Fam Physician       Date:  2015-10       Impact factor: 3.275

Review 2.  Gonorrhoea.

Authors:  Sarah Creighton
Journal:  BMJ Clin Evid       Date:  2011-03-14

Review 3.  Gonorrhoea.

Authors:  Sarah Creighton
Journal:  BMJ Clin Evid       Date:  2014-02-21

Review 4.  Gonorrhoea.

Authors:  John S Moran
Journal:  BMJ Clin Evid       Date:  2007-03-01

Review 5.  Antimicrobial susceptibility testing of Neisseria gonorrhoeae and implications for epidemiology and therapy.

Authors:  T Fekete
Journal:  Clin Microbiol Rev       Date:  1993-01       Impact factor: 26.132

Review 6.  Current and future antimicrobial treatment of gonorrhoea - the rapidly evolving Neisseria gonorrhoeae continues to challenge.

Authors:  Magnus Unemo
Journal:  BMC Infect Dis       Date:  2015-08-21       Impact factor: 3.090

Review 7.  Systematic review and meta-analysis on efficacy of cefixime for treating gonococcal infections.

Authors:  Syed Bilal Tanvir; Syed Saad Bin Qasim; Ali Shariq; Shariq Najeeb; Altaf H Shah
Journal:  Int J Health Sci (Qassim)       Date:  2018 Sep-Oct

8.  Efficacy and Safety of Injectable and Oral Antibiotics in Treating Gonorrhea: A Systematic Review and Network Meta-Analysis.

Authors:  Jiaru Yang; Subhash Dhital; Thomas Naderer
Journal:  J Clin Med       Date:  2019-12-11       Impact factor: 4.241
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.